Jim Simons
HTGM

Jim Simons’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Jim Simons’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,200
Closed -$53K – 4547
2022
Q3 		$53K Sell
7,200
-5,637
-44% -$68.5K ﹤0.01% 3746
2022
Q2 		$159K Buy
12,837
+8,211
+177% +$77K ﹤0.01% 3734
2022
Q1 		$77K Buy
4,626
+75
+2% +$2.41K ﹤0.01% 3838
2021
Q4 		$296K Sell
4,551
-109
-2% -$6.35K ﹤0.01% 3349
2021
Q3 		$319K Sell
4,660
-100
-2% -$7.15K ﹤0.01% 3062
2021
Q2 		$332K Sell
4,760
-6,805
-59% -$368K ﹤0.01% 3111
2021
Q1 		$759K Buy
11,565
+3,597
+45% +$273K ﹤0.01% 2734
2020
Q4 		$458K Sell
7,968
-1,048
-12% -$61K ﹤0.01% 2859
2020
Q3 		$536K Buy
9,016
+5,334
+145% +$476K ﹤0.01% 2792
2020
Q2 		$477K Buy
+3,682
New +$325K ﹤0.01% 2898
2019
Q4 		– Sell
-242
Closed -$29K – 3817
2019
Q3 		$29K Buy
+242
New +$48.7K ﹤0.01% 3358
2017
Q2 		– Sell
-61
Closed -$75K – 3421
2017
Q1 		$75K Sell
61
-262
-81% -$126K ﹤0.01% 3111
2016
Q4 		$130K Buy
323
+79
+32% +$31.5K ﹤0.01% 3063
2016
Q3 		$100K Buy
244
+88
+56% +$39.3K ﹤0.01% 3180
2016
Q2 		$76K Buy
+156
New +$79.2K ﹤0.01% 3198

Other funds holding HTGM

TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HWM
HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Jim Simons's HTGM Position: Q4 2022 in Review

Jim Simons sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2022, closing a stake of 7,200 shares — an estimated $53K sold.

Jim Simons first reported a position in HTGM in Q2 2016 and held it in 15 quarters. The position peaked at $759K in Q1 2021. 10 funds tracked by Wall St. Rank hold HTGM as of Q4 2022.

  • Jim Simons reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Jim Simons sold 7,200 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2022, an estimated $53K.
  • Jim Simons first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2016 and held it in 15 quarters.
  • Jim Simons's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $759K in Q1 2021.
  • 10 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.